Mohan Karkada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohan Karkada has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Marc Mansour
ImmunoVaccine, Inc., Halifax, NS, Canada
3 shared publicationsTara Quinton
ImmunoVaccine, Inc., Halifax, NS, Canada
3 shared publications- Lisa D. MacDonald
ImmunoVaccine, Inc., Halifax, NS, Canada
2 shared publications - Marianne M. Stanford
Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada
2 shared publications - Neil Lorne Berinstein
Sunnybrook Research Institute, University of Toronto
2 shared publications Rita Nigam
ImmunoVaccine, Inc., Halifax, NS, Canada
2 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e14577
Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritoneal cancer (OC): A phase Ib study.
E14577 Background: Survivin is an important protein that regulates apoptosis, proliferation, and angiogenesis of tumors. Increased expression of survivin in various tumors correlates with progression and drug resistance. DPX-Survivac vaccine contains a mix of survivin HLA class I peptides contained in a novel formulation designed to evoke a cytotoxic T cell response against survivin. A phase 1 study (Berinstein et al, Oncoimmunology, 2015) has demonstrated the immunogenicity of DPX-Survivac in combination with metronomic low dose oral cyclophosphamide (mCPA). This study was designed to explore additional dosing schedules that maintain immunogenicity while limiting local injection site reactions in OC. Methods: Stage IIc-IV OC patients with a complete or partial response after first (adjuvant) or second line chemotherapy and with minimal disease were enrolled. Various vaccination schedules as well as boosting without the oil component of DPX-Survivac were tested. Adverse events and dose limiting toxicities were defined by CTCAE v4.03. Vaccine-induced T cell immunity (ELISpot; tetramer analysis) was assessed in purified PBMC. Clinical response was assessed by CT and CA125 using standard RECIST criteria. Results: 36 patients have been treated with different doses and schedules DPX-Survivac vaccination together with mCPA. Several modifications of the dose and schedule resulted in sustained immune responses of varying magnitude and duration. DPX-Survivac was well tolerated. Conclusions: DPX-Survivac in combination with mCPA results in sustained immune responses. This study will allow us to balance the immune response and site of injection profile for different indications including early prevention of recurrence or treatment of small volume active disease. Clinical trial information: NCT01416038.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e14577
Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritoneal cancer (OC): A phase Ib study.
E14577 Background: Survivin is an important protein that regulates apoptosis, proliferation, and angiogenesis of tumors. Increased expression of survivin in various tumors correlates with progression and drug resistance. DPX-Survivac vaccine contains a mix of survivin HLA class I peptides contained in a novel formulation designed to evoke a cytotoxic T cell response against survivin. A phase 1 study (Berinstein et al, Oncoimmunology, 2015) has demonstrated the immunogenicity of DPX-Survivac in combination with metronomic low dose oral cyclophosphamide (mCPA). This study was designed to explore additional dosing schedules that maintain immunogenicity while limiting local injection site reactions in OC. Methods: Stage IIc-IV OC patients with a complete or partial response after first (adjuvant) or second line chemotherapy and with minimal disease were enrolled. Various vaccination schedules as well as boosting without the oil component of DPX-Survivac were tested. Adverse events and dose limiting toxicities were defined by CTCAE v4.03. Vaccine-induced T cell immunity (ELISpot; tetramer analysis) was assessed in purified PBMC. Clinical response was assessed by CT and CA125 using standard RECIST criteria. Results: 36 patients have been treated with different doses and schedules DPX-Survivac vaccination together with mCPA. Several modifications of the dose and schedule resulted in sustained immune responses of varying magnitude and duration. DPX-Survivac was well tolerated. Conclusions: DPX-Survivac in combination with mCPA results in sustained immune responses. This study will allow us to balance the immune response and site of injection profile for different indications including early prevention of recurrence or treatment of small volume active disease. Clinical trial information: NCT01416038.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e14578
A phase 2 clinical trial testing DPX-Survivac and metronomic low dose cyclophosphamide as immunotherapy for patients with recurrent diffuse large b-cell lymphoma.
E14578 Background: Survivin is strongly expressed in tumors of about 60% of diffuse large B-cell lymphoma (DLBCL) patients. DPX-Survivac contains survivin HLA class I peptides in a novel formulation, DepoVax. A phase 1 trial in ovarian cancer patients demonstrated the safety and immunogenicity of DPX-Survivac therapy. A phase 2 trial was initiated to determine the objective response rate, immunogenicity and safety in patients with recurrent, survivin-expressing DLBCL who are not eligible for transplant, or who have recurred after transplant. Methods: 24 subjects with confirmed survivin-positive DLBCL with LDH’s less than 2x normal, are to be enrolled in this study. Patients receive two 0.25 mL priming doses of DPX-Survivac three weeks apart and up to six 0.1 mL boosting doses eight weeks apart in combination with low dose oral metronomic cyclophosphamide. Subjects will be treated for one year or until disease progression. The objective response rate is measured using Modified Cheson criteria. Biopsy and blood specimens will be collected for correlative biomarker and immune analyses. Safety will be documented by CTCAE v4.03 Results: Four subjects to date have been screened or enrolled in this trial, and two have completed priming and at least one boosting vaccination. The treatment was well tolerated. Both of these two subjects had progressive disease on study day 100 and 162, before completing treatment. One demonstrated a robust systemic antigen-specific T cell response. The subject that did not demonstrate immune responses post- vaccination had low peripheral blood lymphocyte counts at study entry. For the subject with a systemic immune response, it correlated with increased T cell infiltrates in the tumor tissue. Tumor biopsy analysis revealed that both patients had expression of PD-1 and PD-L1 within the tumor tissue. Conclusions: Early results suggest that this immunotherapy approach is feasible with patients with recurrent DLBCL. The interim analysis of the current study provides clinical and biological rationale for combining the vaccine/cyclophosphamide therapy with other cancer immunotherapeutic strategies, such as checkpoint modulators. Clinical trial information: NCT02323230.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e14578
A phase 2 clinical trial testing DPX-Survivac and metronomic low dose cyclophosphamide as immunotherapy for patients with recurrent diffuse large b-cell lymphoma.
E14578 Background: Survivin is strongly expressed in tumors of about 60% of diffuse large B-cell lymphoma (DLBCL) patients. DPX-Survivac contains survivin HLA class I peptides in a novel formulation, DepoVax. A phase 1 trial in ovarian cancer patients demonstrated the safety and immunogenicity of DPX-Survivac therapy. A phase 2 trial was initiated to determine the objective response rate, immunogenicity and safety in patients with recurrent, survivin-expressing DLBCL who are not eligible for transplant, or who have recurred after transplant. Methods: 24 subjects with confirmed survivin-positive DLBCL with LDH’s less than 2x normal, are to be enrolled in this study. Patients receive two 0.25 mL priming doses of DPX-Survivac three weeks apart and up to six 0.1 mL boosting doses eight weeks apart in combination with low dose oral metronomic cyclophosphamide. Subjects will be treated for one year or until disease progression. The objective response rate is measured using Modified Cheson criteria. Biopsy and blood specimens will be collected for correlative biomarker and immune analyses. Safety will be documented by CTCAE v4.03 Results: Four subjects to date have been screened or enrolled in this trial, and two have completed priming and at least one boosting vaccination. The treatment was well tolerated. Both of these two subjects had progressive disease on study day 100 and 162, before completing treatment. One demonstrated a robust systemic antigen-specific T cell response. The subject that did not demonstrate immune responses post- vaccination had low peripheral blood lymphocyte counts at study entry. For the subject with a systemic immune response, it correlated with increased T cell infiltrates in the tumor tissue. Tumor biopsy analysis revealed that both patients had expression of PD-1 and PD-L1 within the tumor tissue. Conclusions: Early results suggest that this immunotherapy approach is feasible with patients with recurrent DLBCL. The interim analysis of the current study provides clinical and biological rationale for combining the vaccine/cyclophosphamide therapy with other cancer immunotherapeutic strategies, such as checkpoint modulators. Clinical trial information: NCT02323230.
- Open Access
- 7 March 2013
- Published by Wiley in ISRN Oncology
- Vol. 2013, 1-13
Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
A successful cancer vaccine needs to overcome the effects of immune-suppressor cells such as Treg lymphocytes, suppressive cytokine-secreting Tr1 cells, and myeloid-derived suppressor cells (MDSCs), while enhancing tumor-specific immune responses. Given the relative poor efficacy associated with current cancer vaccines, a novel vaccine platform called (DPX) was developed. C3 tumor-challenged mice were immunized with HPV-E7 peptide in DPX- or conventional-emulsion- (CE-) based vaccine. While control mice showed marked increase in Treg/MDSCs in spleen and blood, in mice treated with DPX-E7 the levels remained similar to tumor-free naive mice. Such differences were also seen within the tumor. Antigen-specific IL10-secreting CD4/CD8 T cells and TGF-β+CD8+ T cell frequencies were increased significantly in CE-treated and control mice in contrast to DPX-E7-immunized mice. Analysis of tumor-infiltrating cells revealed higher frequency of suppressor cells in untreated controls than in DPX-E7 group while the converse was true for tumor-infiltrating CD8 T cells. Immunization of tumor-bearing HLA-A2 transgenic mice with human vaccine DPX-0907, a peptide-based vaccine for breast/ovarian/prostate cancers, showed efficient induction of immune response to cancer peptides despite the presence of suppressor cells. Thus, this study provides the rationale for using DPX-based cancer vaccines in immune-suppressed cancer patients, to induce effective anticancer immunity.- 7 March 2013
- Published by Wiley in ISRN Oncology
- Vol. 2013, 1-13
Open AccessTumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
A successful cancer vaccine needs to overcome the effects of immune-suppressor cells such as Treg lymphocytes, suppressive cytokine-secreting Tr1 cells, and myeloid-derived suppressor cells (MDSCs), while enhancing tumor-specific immune responses. Given the relative poor efficacy associated with current cancer vaccines, a novel vaccine platform called (DPX) was developed. C3 tumor-challenged mice were immunized with HPV-E7 peptide in DPX- or conventional-emulsion- (CE-) based vaccine. While control mice showed marked increase in Treg/MDSCs in spleen and blood, in mice treated with DPX-E7 the levels remained similar to tumor-free naive mice. Such differences were also seen within the tumor. Antigen-specific IL10-secreting CD4/CD8 T cells and TGF-β+CD8+ T cell frequencies were increased significantly in CE-treated and control mice in contrast to DPX-E7-immunized mice. Analysis of tumor-infiltrating cells revealed higher frequency of suppressor cells in untreated controls than in DPX-E7 group while the converse was true for tumor-infiltrating CD8 T cells. Immunization of tumor-bearing HLA-A2 transgenic mice with human vaccine DPX-0907, a peptide-based vaccine for breast/ovarian/prostate cancers, showed efficient induction of immune response to cancer peptides despite the presence of suppressor cells. Thus, this study provides the rationale for using DPX-based cancer vaccines in immune-suppressed cancer patients, to induce effective anticancer immunity. - Open Access
- 1 July 2012
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 189 (1) , 337-346
Differing Requirements for CCR4, E-Selectin, and α4β1 for the Migration of Memory CD4 and Activated T Cells to Dermal Inflammation
CCR4 on T cells is suggested to mediate skin homing in mice. Our objective was to determine the interaction of CCR4, E-selectin ligand (ESL), and α4β1 on memory and activated T cells in recruitment to dermal inflammation. mAbs to rat CCR4 were developed. CCR4 was on 5–21% of memory CD4 cells, and 20% were also ESL+. Anti–TCR-activated CD4 and CD8 cells were 40–55% CCR4+, and ∼75% of both CCR4+ and CCR4− cells were ESL+. CCR4+ memory CD4 cells migrated 4- to 7-fold more to dermal inflammation induced by IFN-γ, TNF, TLR agonists, and delayed-type hypersensitivity than CCR4− cells. CCR4+ activated CD4 cells migrated only 5–50% more than CCR4− cells to these sites. E-selectin blockade inhibited ∼60% of CCR4+ activated CD4 cell migration but was less effective on memory cells where α4β1 was more important. Anti-α4β1 also inhibited CCR4− activated CD4 cells more than CCR4+ cells. Anti–E-selectin reduced activated CD8 more than CD4 cell migration. These findings modify our understanding of CCR4, ESL, α4β1, and dermal tropism. There is no strict relationship between CCR4 and ESL for skin homing of CD4 cells, because the activation state and inflammatory stimulus are critical determinants. Dermal homing memory CD4 cells express CCR4 and depend more on α4β1 than ESL. Activated CD4 cells do not require CCR4, but CCR4+ cells are more dependent on ESL than on α4β1, and CCR4− cells preferentially use α4β1. The differentiation from activated to memory CD4 cells increases the dependence on CCR4 for skin homing and decreases the requirement for ESL.
- 1 July 2012
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 189 (1) , 337-346
Open AccessDiffering Requirements for CCR4, E-Selectin, and α4β1 for the Migration of Memory CD4 and Activated T Cells to Dermal Inflammation
CCR4 on T cells is suggested to mediate skin homing in mice. Our objective was to determine the interaction of CCR4, E-selectin ligand (ESL), and α4β1 on memory and activated T cells in recruitment to dermal inflammation. mAbs to rat CCR4 were developed. CCR4 was on 5–21% of memory CD4 cells, and 20% were also ESL+. Anti–TCR-activated CD4 and CD8 cells were 40–55% CCR4+, and ∼75% of both CCR4+ and CCR4− cells were ESL+. CCR4+ memory CD4 cells migrated 4- to 7-fold more to dermal inflammation induced by IFN-γ, TNF, TLR agonists, and delayed-type hypersensitivity than CCR4− cells. CCR4+ activated CD4 cells migrated only 5–50% more than CCR4− cells to these sites. E-selectin blockade inhibited ∼60% of CCR4+ activated CD4 cell migration but was less effective on memory cells where α4β1 was more important. Anti-α4β1 also inhibited CCR4− activated CD4 cells more than CCR4+ cells. Anti–E-selectin reduced activated CD8 more than CD4 cell migration. These findings modify our understanding of CCR4, ESL, α4β1, and dermal tropism. There is no strict relationship between CCR4 and ESL for skin homing of CD4 cells, because the activation state and inflammatory stimulus are critical determinants. Dermal homing memory CD4 cells express CCR4 and depend more on α4β1 than ESL. Activated CD4 cells do not require CCR4, but CCR4+ cells are more dependent on ESL than on α4β1, and CCR4− cells preferentially use α4β1. The differentiation from activated to memory CD4 cells increases the dependence on CCR4 for skin homing and decreases the requirement for ESL.
- Open Access
- 7 July 2011
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (11) , 3467-3476
Coexpression of chemokine receptors CCR5, CXCR3, and CCR4 and ligands for P‐ and E‐selectin on T lymphocytes of patients with juvenile idiopathic arthritis
Objective To investigate P- and E-selectin ligand coexpression with chemokine receptors (CKRs) on T cells in the synovial fluid (SF) and blood of children with juvenile idiopathic arthritis (JIA). Methods Sixteen patients with polyarticular or persistent oligoarticular JIA (ages 5.3–15.1 years) were studied. SF and venous blood were collected, and immunostaining for the expression of CCR4, CCR5, CXCR3, and P- or E-selectin ligands was performed. Results Compared to blood, SF was greatly enriched for CD4+ T cells bearing CCR5, CCR4, CXCR3, and both P- and E-selectin ligand. Twenty-five percent of the CD4+ T cells in SF expressed both CCR5 and CCR4, some also coexpressing CXCR3. Such cells were rare in blood. Half of the few CCR5+ T cells in blood coexpressed P- or E-selectin ligand, a phenotype that was enriched up to 50-fold in SF. A minority of CCR4+ and CXCR3+ cells in blood (∼25%) coexpressed selectin ligand; these were enriched 4–8-fold in SF. Most CCR4-expressing CD4+ T cells expressed both E-selectin ligand and cutaneous lymphocyte antigen. Conclusion CCR4-, CCR5-, CXCR3-, and selectin ligand–expressing CD4+ T cells preferentially accumulate in the joints of children with JIA. The marked enrichment of CCR5+ T cells coexpressing P-selectin and/or E-selectin ligand in CD4+ SF T cells suggests that the few such cells in blood selectively migrate to inflamed joints via endothelial P- and E-selectin– and CCR5-activating chemokines. The predominance of CCR4-expressing CD4+ T cells coexpressing E-selectin ligand suggests that such cells migrate not only to areas of cutaneous inflammation, as previously reported, but also to the joints in JIA. Combined targeting of CCR5- and E-selectin–dependent mechanisms may be a relevant treatment strategy.
- 7 July 2011
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (11) , 3467-3476
Open AccessCoexpression of chemokine receptors CCR5, CXCR3, and CCR4 and ligands for P‐ and E‐selectin on T lymphocytes of patients with juvenile idiopathic arthritis
Objective To investigate P- and E-selectin ligand coexpression with chemokine receptors (CKRs) on T cells in the synovial fluid (SF) and blood of children with juvenile idiopathic arthritis (JIA). Methods Sixteen patients with polyarticular or persistent oligoarticular JIA (ages 5.3–15.1 years) were studied. SF and venous blood were collected, and immunostaining for the expression of CCR4, CCR5, CXCR3, and P- or E-selectin ligands was performed. Results Compared to blood, SF was greatly enriched for CD4+ T cells bearing CCR5, CCR4, CXCR3, and both P- and E-selectin ligand. Twenty-five percent of the CD4+ T cells in SF expressed both CCR5 and CCR4, some also coexpressing CXCR3. Such cells were rare in blood. Half of the few CCR5+ T cells in blood coexpressed P- or E-selectin ligand, a phenotype that was enriched up to 50-fold in SF. A minority of CCR4+ and CXCR3+ cells in blood (∼25%) coexpressed selectin ligand; these were enriched 4–8-fold in SF. Most CCR4-expressing CD4+ T cells expressed both E-selectin ligand and cutaneous lymphocyte antigen. Conclusion CCR4-, CCR5-, CXCR3-, and selectin ligand–expressing CD4+ T cells preferentially accumulate in the joints of children with JIA. The marked enrichment of CCR5+ T cells coexpressing P-selectin and/or E-selectin ligand in CD4+ SF T cells suggests that the few such cells in blood selectively migrate to inflamed joints via endothelial P- and E-selectin– and CCR5-activating chemokines. The predominance of CCR4-expressing CD4+ T cells coexpressing E-selectin ligand suggests that such cells migrate not only to areas of cutaneous inflammation, as previously reported, but also to the joints in JIA. Combined targeting of CCR5- and E-selectin–dependent mechanisms may be a relevant treatment strategy.